Introduction

The preimplantation genetic testing (PGT) market is gaining strong momentum as assisted reproductive technologies (ART) continue to evolve globally. Preimplantation genetic testing is a procedure used during in-vitro fertilization (IVF) to screen embryos for genetic abnormalities before implantation, improving the chances of a healthy pregnancy and reducing the risk of inherited disorders.

Increasing infertility rates, delayed pregnancies, and rising awareness of genetic disorders are key factors driving the adoption of PGT. In addition, advancements in genomic technologies such as next-generation sequencing (NGS) have significantly improved the accuracy and efficiency of embryo screening.

Growing acceptance of IVF treatments and expanding fertility clinic networks across developed and emerging economies are further accelerating market growth.

Preimplantation Genetic Testing Market Size

The global preimplantation genetic testing market size was valued at USD 848.11 million in 2024.
It is expected to grow from USD 905.87 million in 2025 to reach USD 1534.47 million by 2033, exhibiting a CAGR of 6.81% during the forecast period (2025–2033).

Get Full Report Now: https://straitsresearch.com/report/preimplantation-genetic-testing-market

Market Drivers and Challenges

Market Drivers

One of the primary drivers of the preimplantation genetic testing market is the rising prevalence of infertility worldwide. Lifestyle changes, delayed pregnancies, stress, and environmental factors have significantly contributed to fertility challenges, increasing demand for IVF and genetic testing services.

Growing awareness of genetic disorders such as Down syndrome, cystic fibrosis, and Tay-Sachs disease is also boosting adoption of PGT. Couples are increasingly opting for embryo screening to ensure healthy pregnancies.

Advancements in genetic testing technologies, particularly next-generation sequencing (NGS) and polymerase chain reaction (PCR), have improved diagnostic accuracy and reduced turnaround time, supporting market expansion.

Increasing acceptance of assisted reproductive technologies (ART) in developing countries is further contributing to market growth.

Additionally, supportive government policies and reimbursement improvements in certain regions are making fertility treatments more accessible.

Get Your Sample Report Here: https://straitsresearch.com/report/preimplantation-genetic-testing-market/request-sample

Market Challenges

Despite strong growth, the market faces several challenges. High cost of IVF and genetic testing procedures remains a major barrier, especially in low- and middle-income countries.

Ethical concerns related to embryo selection and genetic manipulation continue to raise debates in the medical and social communities.

Limited access to advanced fertility clinics in rural and underdeveloped regions restricts market penetration.

Complex regulatory frameworks for genetic testing and reproductive technologies can delay approvals and commercialization.

Additionally, lack of awareness in certain populations still limits widespread adoption of PGT services.

Market Segmentation

By Type

The market is segmented into preimplantation genetic diagnosis (PGD), preimplantation genetic screening (PGS), and preimplantation genetic testing for aneuploidy (PGT-A), monogenic disorders (PGT-M), and structural rearrangements (PGT-SR).

PGT-A holds a significant share as it helps detect chromosomal abnormalities and improves IVF success rates.

PGT-M is widely used for identifying single-gene disorders such as cystic fibrosis and sickle cell anemia.

PGT-SR is used for detecting chromosomal structural rearrangements in embryos.

By Technology

The market is segmented into polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH), and next-generation sequencing (NGS).

NGS dominates the market due to its high accuracy, scalability, and ability to analyze multiple genetic conditions simultaneously.

PCR is widely used for targeted genetic analysis, while FISH is used for chromosomal screening in early-stage testing.

By Application

The market is segmented into aneuploidy screening, gender selection, structural rearrangement detection, and single-gene disorder testing.

Aneuploidy screening leads the segment due to its importance in improving IVF success rates and reducing miscarriage risks.

Gender selection is used in cases of sex-linked genetic disorders.

By End User

The market is segmented into fertility clinics, hospitals, and research and academic institutes.

Fertility clinics dominate the market due to increasing IVF procedures globally.

Hospitals are expanding their reproductive medicine departments, contributing to market growth.

Research institutes are focusing on advancements in genetic testing technologies.

By Region

The market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

North America leads the market due to advanced healthcare infrastructure, high IVF adoption rates, and strong presence of genetic testing companies.

Europe follows closely with supportive regulations and increasing awareness of reproductive health.

Asia-Pacific is the fastest-growing region due to rising infertility rates, medical tourism, and expanding fertility clinic networks.

Top Players Analysis

1. Illumina Inc.
   Illumina is a global leader in genomic sequencing technologies widely used in preimplantation genetic testing applications.

2. Thermo Fisher Scientific Inc.
   Thermo Fisher provides advanced genetic analysis tools and reagents used in IVF and embryo screening procedures.

3. CooperSurgical Inc.
   CooperSurgical specializes in reproductive health solutions, including comprehensive PGT testing platforms.

4. Igenomix
   Igenomix is a key player offering genetic testing services for fertility clinics worldwide.

5. Natera Inc.
   Natera provides advanced genetic testing solutions focusing on reproductive health and embryo screening.

6. Quest Diagnostics Incorporated
   Quest Diagnostics offers genetic testing services, including PGT solutions for fertility applications.

7. Genea Limited
   Genea is an Australian fertility company specializing in IVF and genetic testing services.

8. PerkinElmer Inc.
   PerkinElmer provides diagnostic technologies and genetic testing platforms for reproductive medicine.

9. CooperGenomics
   CooperGenomics focuses on preimplantation genetic testing services and reproductive genetics solutions.

10. Illumina Clinical Services Laboratory
    This division of Illumina provides advanced clinical genetic testing services supporting IVF clinics globally.

Conclusion

The preimplantation genetic testing market is witnessing strong growth driven by increasing infertility rates, advancements in genetic technologies, and rising awareness of reproductive health. As IVF procedures become more accessible and accepted globally, the demand for accurate embryo screening continues to rise.

Although challenges such as high costs and ethical concerns persist, ongoing technological innovation and expanding fertility clinic networks are expected to drive sustained market growth. The future of PGT lies in precision medicine, improved accessibility, and enhanced genetic testing accuracy.

FAQs

What is preimplantation genetic testing?

Preimplantation genetic testing is a procedure used during IVF to screen embryos for genetic abnormalities before implantation.

What is driving the PGT market growth?

Rising infertility rates, genetic disorder awareness, and advancements in genomic technologies are key drivers.

Which segment dominates the market?

PGT-A (aneuploidy screening) dominates due to its role in improving IVF success rates.

What are the major challenges?

High costs, ethical concerns, and limited access to fertility clinics are major challenges.

Which region leads the market?

North America leads due to advanced reproductive healthcare infrastructure and high IVF adoption rates.

About Us: 

Straits Research is a leading research and intelligence organisation, specialising in research, analytics, and advisory services, along with providing business insights & research reports.

Contact Us:

Email: [email protected]

Tel: +1 646 905 0080 (U.S.), +44 203 695 0070 (U.K.)